Dianqing Sun

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Topics

Pulmonary Tuberculosis

Clostridium Difficile

Top Venues

ACS infectious diseases

Molecules (Basel, Switzerland)

ACS chemical biology

ACS combinatorial science

This page only lists publications with an associated author ORCID identifier.

Publications

Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases (2024)
Dianqing Sun
Recent Advances in Macrocyclic Drugs and Microwave-Assisted and/or Solid-Supported Synthesis of Macrocycles. Molecules (Basel, Switzerland) 27 (3) (2022)
Pamela K Garcia, Thirunavukkarasu Annamalai, Wenjie Wang, Raven S Bell, Duc Le, Paula Martin Pancorbo, Sabah Sikandar, Ahmed Seddek, Xufen Yu, Dianqing Sun, Anne-Catrin Uhlemann, Purushottam B Tiwari, Fenfei Leng, Yuk-Ching Tse-Dinh
Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound. PloS one 14 (2) (2019)
Jesse A Jones, Allan M Prior, Ravi K R Marreddy, Rebecca D Wahrmund, Julian G Hurdle, Dianqing Sun, Kirk E Hevener
Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity. ACS chemical biology 14 (7) (2019)
Allan M Prior, Dianqing Sun
Total synthesis of diazaquinomycins H and J using double Knorr cyclization in the presence of triisopropylsilane. RSC advances 9 (4) (2019)
Allan M Prior, Taylor Hori, Ashriel Fishman, Dianqing Sun
Recent Reports of Solid-Phase Cyclohexapeptide Synthesis and Applications. Molecules (Basel, Switzerland) 23 (6) (2018)
Lissa S Tsutsumi, John M Elmore, Uyen T Dang, Miranda J Wallace, Ravikanthreddy Marreddy, Robin B Lee, Ghee T Tan, Julian G Hurdle, Richard E Lee, Dianqing Sun
Solid-Phase Synthesis and Antibacterial Activity of Cyclohexapeptide Wollamide B Analogs. ACS combinatorial science 20 (3) (2018)
Ravi K R Marreddy, Xiaoqian Wu, Madhab Sapkota, Allan M Prior, Jesse A Jones, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection. ACS infectious diseases 5 (2) (2018)